Literature DB >> 28529843

Deconstructing the Complexity of TGFβ Signaling in Hematopoietic Stem Cells: Quiescence and Beyond.

Ashwini Hinge1, Marie-Dominique Filippi1.   

Abstract

The hematopoietic system is highly dynamic and must constantly produce new blood cells every day. Mature blood cells all derive from a pool of rare long-lived hematopoietic stem cells (HSCs) that are mostly quiescent but occasionally divide and self-renew in order to maintain the stem cell pool and continuous replenishment of mature blood cells throughout life. A tight control of HSC self-renewal, commitment to differentiation and maintenance of quiescence states is necessary for lifelong blood supply. Transforming growth factor-β (TGF-β) is a critical regulator hematopoietic cell functions. It is a potent inhibitor of hematopoietic cell growth. However, TGFβ functions are more complex and largely context-dependent. Emerging evidence suggests a role in aging, cell identity and cell fate decisions. Here, we will review the role of TGF-β and downstream signaling in normal HSC functions, in HSC quiescence and beyond.

Entities:  

Keywords:  TGFβ; fate determination; hematopoietic stem cell; quiescence

Year:  2016        PMID: 28529843      PMCID: PMC5436728          DOI: 10.1007/s40778-016-0069-x

Source DB:  PubMed          Journal:  Curr Stem Cell Rep


  81 in total

1.  Hematopoiesis controlled by distinct TIF1gamma and Smad4 branches of the TGFbeta pathway.

Authors:  Wei He; David C Dorn; Hediye Erdjument-Bromage; Paul Tempst; Malcolm A S Moore; Joan Massagué
Journal:  Cell       Date:  2006-06-02       Impact factor: 41.582

2.  The gata1/pu.1 lineage fate paradigm varies between blood populations and is modulated by tif1γ.

Authors:  Rui Monteiro; Claire Pouget; Roger Patient
Journal:  EMBO J       Date:  2011-02-18       Impact factor: 11.598

3.  Hematopoietic stem cell subtypes expand differentially during development and display distinct lymphopoietic programs.

Authors:  Claudia Benz; Michael R Copley; David G Kent; Stefan Wohrer; Adrian Cortes; Nima Aghaeepour; Elaine Ma; Heidi Mader; Keegan Rowe; Christopher Day; David Treloar; Ryan R Brinkman; Connie J Eaves
Journal:  Cell Stem Cell       Date:  2012-03-02       Impact factor: 24.633

Review 4.  Hematopoietic Stem Cell and Its Bone Marrow Niche.

Authors:  V W C Yu; D T Scadden
Journal:  Curr Top Dev Biol       Date:  2016-03-21       Impact factor: 4.897

Review 5.  Latent transforming growth factor-beta: structural features and mechanisms of activation.

Authors:  J S Munger; J G Harpel; P E Gleizes; R Mazzieri; I Nunes; D B Rifkin
Journal:  Kidney Int       Date:  1997-05       Impact factor: 10.612

6.  Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation.

Authors:  Joseph M Scandura; Piernicola Boccuni; Joan Massagué; Stephen D Nimer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

7.  Reduction in levels of the cyclin-dependent kinase inhibitor p27(kip-1) coupled with transforming growth factor beta neutralization induces cell-cycle entry and increases retroviral transduction of primitive human hematopoietic cells.

Authors:  M A Dao; N Taylor; J A Nolta
Journal:  Proc Natl Acad Sci U S A       Date:  1998-10-27       Impact factor: 11.205

8.  Differential activation of MAPK signaling pathways by TGF-beta1 forms the molecular mechanism behind its dose-dependent bidirectional effects on hematopoiesis.

Authors:  V P Kale
Journal:  Stem Cells Dev       Date:  2004-02       Impact factor: 3.272

Review 9.  Complex and context dependent regulation of hematopoiesis by TGF-beta superfamily signaling.

Authors:  Sofie Singbrant Söderberg; Göran Karlsson; Stefan Karlsson
Journal:  Ann N Y Acad Sci       Date:  2009-09       Impact factor: 5.691

10.  Transforming growth factor beta 1 is an inducer of erythroid differentiation.

Authors:  G Krystal; V Lam; W Dragowska; C Takahashi; J Appel; A Gontier; A Jenkins; H Lam; L Quon; P Lansdorp
Journal:  J Exp Med       Date:  1994-09-01       Impact factor: 14.307

View more
  7 in total

Review 1.  Biological basis for efficacy of activin receptor ligand traps in myelodysplastic syndromes.

Authors:  Amit Verma; Rajasekhar Nvs Suragani; Srinivas Aluri; Nishi Shah; Tushar D Bhagat; Mark J Alexander; Rami Komrokji; Ravi Kumar
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

2.  Spatial and biochemical interactions between bone marrow adipose tissue and hematopoietic stem and progenitor cells in rhesus macaques.

Authors:  Jacob J Robino; Nathalie Pamir; Sara Rosario; Lindsey B Crawford; Benjamin J Burwitz; Charles T Roberts; Peter Kurre; Oleg Varlamov
Journal:  Bone       Date:  2020-01-20       Impact factor: 4.398

Review 3.  The role of TGFβ in hematopoiesis and myeloid disorders.

Authors:  Alex Bataller; Guillermo Montalban-Bravo; Kelly A Soltysiak; Guillermo Garcia-Manero
Journal:  Leukemia       Date:  2019-02-28       Impact factor: 11.528

4.  Combination of SB431542, Chir9901, and Bpv as a novel supplement in the culture of umbilical cord blood hematopoietic stem cells.

Authors:  Morteza Zarrabi; Elaheh Afzal; Mohammad Hassan Asghari; Marzieh Ebrahimi
Journal:  Stem Cell Res Ther       Date:  2020-11-09       Impact factor: 6.832

5.  Transforming growth factor-β signaling modifies the hematopoietic acute inflammatory response to drive bone marrow failure.

Authors:  Jose Javier; Ashwini Hinge; James Bartram; Juying Xu; Marie-Dominique Filippi
Journal:  Haematologica       Date:  2022-06-01       Impact factor: 11.047

Review 6.  In the spotlight: the role of TGFβ signalling in haematopoietic stem and progenitor cell emergence.

Authors:  Roshana Thambyrajah; Rui Monteiro
Journal:  Biochem Soc Trans       Date:  2022-04-29       Impact factor: 4.919

Review 7.  Myeloid-Derived Suppressor Cells: New Insights into the Pathogenesis and Therapy of MDS.

Authors:  Maria Velegraki; Andrew Stiff; Helen A Papadaki; Zihai Li
Journal:  J Clin Med       Date:  2022-08-21       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.